Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Mesenchymal stem cell therapy | 1 |
Herbal medicine | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AKR1C2 agonists |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Feb 2025 |
Sponsor / Collaborator |
Start Date25 Jul 2024 |
Sponsor / Collaborator |
Start Date17 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Autologous Adipose Tissue-Derived Mesenchymal Stem Cell(Bangabandhu Sheikh Mujib Medical University) | - | Phase 3 Clinical |
Papaya Leaf Extract | Dengue More | Phase 3 |
Solasodine ( Class I PI3K ) | Arsenical keratosis More | Pending |
Eggplant peel extract | Arsenical keratosis More | Pending |
Celosia extract | Arsenical keratosis More | Pending |